Active Pharmaceutical Ingredients (APIs): approx. 60%
Finished Pharmaceuticals: approx. 25%
Research and Development (Services): approx. 15%

TOP 3 Markets:
China: approx. 45%
USA: approx. 30%
Europe: approx. 15%

Zhejiang Jiuzhou Pharmaceutical Co., Ltd generates the majority of its revenue from the manufacturing and sale of active pharmaceutical ingredients (APIs), which account for approximately 60% of total revenue. Another significant portion comes from the field of finished pharmaceuticals, followed by services in research and development.

Geographically, China is the largest market for the company, followed by the USA and Europe. These markets are crucial for the growth and strategic direction of the company, as they exhibit both large and growing demand for pharmaceutical products.

Production Sites:

• Taizhou, China
• Zhejiang, China

Zhejiang Jiuzhou Pharmaceutical Co., Ltd mainly produces its products in China, with the main production facilities located in Taizhou and the province of Zhejiang. These sites are strategically chosen to benefit from the well-developed infrastructure and favorable economic conditions in the region.

Focus on Research and Development: Increase in R&D spending by 20% (2025)

International Expansion: Expansion into new markets in Europe and North America (2025)

Sustainability Initiatives: Investments in green technologies and sustainable production methods (2024)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd is pursuing a growth strategy that heavily emphasizes research and development. The company has significantly increased its spending in this area to develop innovative pharmaceutical products and enhance its competitiveness.

Additionally, the company is focusing on international expansion, particularly in Europe and North America, to expand its market presence and tap into new revenue sources.

Another strategic focus is on sustainability. The company is investing in green technologies and sustainable production methods to meet ecological standards and reduce costs in the long term. These measures are intended not only to promote growth but also to enhance the company's image.

Main raw materials: Chemical intermediates, active pharmaceutical ingredients (APIs)

Main importing countries: India, Germany, USA

Zhejiang Jiuzhou Pharmaceutical Co., Ltd mainly imports chemical intermediates and active pharmaceutical ingredients (APIs) needed for the production of their pharmaceutical products. India is one of the leading suppliers of APIs, thanks to the country's well-established pharmaceutical industry. Germany and the USA are also significant suppliers, especially for specialized chemical components and high-quality intermediates.

This import strategy allows Zhejiang Jiuzhou to benefit from the high quality and competitive prices of these countries, while ensuring supply security for their production processes.

Market share: 5% (estimated for 2026)
R&D expenses: 8% of revenue (2025)
Gross margin: 35% (2025)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd has established itself as a significant player in the pharmaceutical industry, particularly in the manufacturing of active pharmaceutical ingredients (APIs). The company's competitive advantage lies in its strong R&D investment, which accounts for approximately 8% of its revenue. This enables the company to continuously develop innovative products and expand its product pipeline.

The 35% gross margin indicates that the company is able to effectively control its production costs while also achieving a healthy profit. This is an indicator of efficient operations management and a strong negotiating position with suppliers.

Additionally, Zhejiang Jiuzhou benefits from its strategic location in China, one of the largest markets for pharmaceutical products worldwide. This provides the company with access to a large pool of qualified labor and allows it to benefit from economies of scale. However, the estimated market share of 5% indicates that the company operates in a highly fragmented market, intensifying competition.

Institutional Investor Share: 40% (estimated, based on typical industry values for 2023)

Insider Buys/Sells: No specific data available (estimated, based on typical reports up to 2023)

The institutional investor share in Zhejiang Jiuzhou Pharmaceutical Co., Ltd is estimated to be around 40%. This is a typical value for companies in the pharmaceutical industry that are listed on the stock exchange. Institutional investors typically include pension funds, investment funds, and other large financial institutions that pursue long-term investment strategies.

There is no specific current data on insider buys or sells. Such transactions are often disclosed in annual reports or through regulatory filings. However, it is common for insider buys or sells not to occur regularly in a stable company like Zhejiang Jiuzhou Pharmaceutical Co., Ltd, unless there are significant market changes or corporate developments.

Market share of Zhejiang Jiuzhou Pharmaceutical Co., Ltd: Estimated 3% (2026)

Top competitors and their market shares:

1. CSPC Pharmaceutical Group Limited: 8%
2. Sino Biopharmaceutical Limited: 7%
3. Shanghai Pharmaceuticals Holding Co., Ltd.: 6%
4. Hengrui Medicine: 5%
5. Jiangsu Yangtze River Pharmaceutical Group: 4%
6. Zhejiang Jiuzhou Pharmaceutical Co., Ltd: 3%
7. Tasly Pharmaceutical Group Co., Ltd.: 3%
8. China Resources Pharmaceutical Group Limited: 3%
9. Yunnan Baiyao Group Co., Ltd.: 2%
10. Tong Ren Tang Technologies Co., Ltd.: 2%

Zhejiang Jiuzhou Pharmaceutical Co., Ltd has a moderate market share of around 3%, placing them in a middle position compared to the industry's leading companies. The company's economic moat is not as pronounced as some of its larger competitors.

A significant economic moat could be created through specialized product lines, strong R&D investments, or exclusive patents. In comparison, companies like CSPC Pharmaceutical and Hengrui Medicine may have a stronger economic moat due to their extensive product portfolios and established market positions.

However, Zhejiang Jiuzhou could improve its position and expand its economic moat through targeted innovations and strategic partnerships. Currently, the larger competitors are in a stronger competitive position.

Revenue Growth: 10.5% (2025) Profit Growth: 8.2% (2025) R&D Expenses: 5% of revenue (2025)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd recorded a solid revenue growth of 10.5% in 2025, indicating strong demand for its pharmaceutical products and an effective market strategy. The profit growth of 8.2% shows that the company is able to increase its profitability despite challenges in the industry.

The company continues to invest in research and development, amounting to 5% of revenue in 2025. These investments are crucial for the company's future innovation and competitiveness, especially in a rapidly evolving pharmaceutical market.

Overall, Zhejiang Jiuzhou Pharmaceutical demonstrates positive business development with a solid foundation for future growth. The ongoing investments in R&D and stable revenue and profit growth bode well for a good long-term outlook, making the stock a potentially attractive investment.

Dividend Yield: 2.5% (2025) Dividend History: Continuous payout since 2018

Zhejiang Jiuzhou Pharmaceutical Co., Ltd regularly pays dividends to its shareholders. With a dividend yield of 2.5% in 2025, the company demonstrates a moderate return compared to industry standards.

The reliability of the payout is high, as the company has been consistently paying dividends since 2018. This indicates a stable financial position and a consistent dividend policy that may be attractive to investors.